Overview of Immunotherapy

Laura J. Zitella, R. Donald Harvey and Mollie Reed


Posted: 12/1/2017
Expires: 11/30/2018
Estimated time to complete: 2 hours and 15 minutes

Instructions for Earning CE credit

This activity has expired, credit is no longer available.





Overview of the Immune Systtem Full Program


Chapter 1
Overview of Immunotherapy


Chapter 2
Talimogene Laherparepvec T-VEC


Chapter 3
Immune Related Adverse Events

rowCount++; var rowCount = 0;

Overview of the Immune Systtem Full Program


Chapter 1
Overview of Immunotherapy


Chapter 2
Talimogene Laherparepvec T-VEC


Chapter 3
Immune Related Adverse Events

rowCount++;
 

Quick Tips

Is programmed cell death ligand 1 (PD-L1) testing necessary?
When should you image patients to assess response to immunotherapy?
Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?
What are the mechanisms of action and adverse effects of these agents?
How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?
What cancers are most likely to respond to immunotherapy?
How do you educate patients about the timing of early and latent side effects?
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.